Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

[1]  J. Gunter,et al.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease , 2012, Neurology.

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[3]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[4]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[5]  John X. Morris,et al.  Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease , 2011, Neurology.

[6]  C. Rowe,et al.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.

[7]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[8]  A. Wallin,et al.  Cognitive Profiles of Incipient Dementia in the Goteborg MCI Study , 2010, Dementia and Geriatric Cognitive Disorders.

[9]  M. Blankenstein,et al.  Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid β (1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop , 2010, International journal of Alzheimer's disease.

[10]  F. Jessen,et al.  Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. , 2010, Archives of general psychiatry.

[11]  D. Brooks,et al.  11C-PIB PET in subjective cognitive impairment , 2010, European Psychiatry.

[12]  W. M. van der Flier,et al.  Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. , 2010, Clinical chemistry.

[13]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[14]  P. Visser,et al.  Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. , 2010, Journal of Alzheimer's disease : JAD.

[15]  Oscar L. Lopez,et al.  Telephone Interview for Cognitive Status , 2009, Neuroepidemiology.

[16]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[17]  W. M. van der Flier,et al.  CSF biomarkers predict rate of cognitive decline in Alzheimer disease , 2009, Neurology.

[18]  John Hardy,et al.  The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal , 2009, Journal of neurochemistry.

[19]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[20]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[21]  Magda Tsolaki,et al.  Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study , 2009, The Lancet Neurology.

[22]  A. Mitchell,et al.  CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer’s disease: a meta-analysis of 51 studies , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[23]  H. Braak,et al.  Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship , 2009, Journal of neuropathology and experimental neurology.

[24]  W. M. van der Flier,et al.  CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. , 2009, Journal of Alzheimer's disease : JAD.

[25]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[26]  O. Forlenza,et al.  Do CSF total tau, phosphorylated tau, and β-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[27]  K. Blennow,et al.  Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI , 2007, Neurology.

[28]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[29]  I. Sokal,et al.  CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment , 2007, Neurology.

[30]  K. Blennow,et al.  Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly , 2007, Dementia and Geriatric Cognitive Disorders.

[31]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[32]  S. Bouwens,et al.  Telefonisch Interview Cognitieve Status (TICS): psychometrische aspecten , 2007 .

[33]  K. Blennow,et al.  Cerebrospinal fluid β-amyloid 1–42 concentration may predict cognitive decline in older women , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  F. Verhey,et al.  [The psychometric properties of the Dutch version of the Telephone Interview Cognitive Status (TICS)]. , 2007, Tijdschrift voor gerontologie en geriatrie.

[35]  G. Schellenberg,et al.  CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. , 2007, Neurology.

[36]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[37]  E. Tangalos,et al.  Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.

[38]  K. Blennow,et al.  CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.

[39]  A Drzezga,et al.  Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. , 2002, Archives of neurology.

[40]  P. Deyn,et al.  Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF , 1999, Neurology.

[41]  L. Bouter,et al.  Association between memory complaints and incident Alzheimer's disease in elderly people with normal baseline cognition. , 1999, The American journal of psychiatry.

[42]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[43]  J. Price,et al.  Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.

[44]  H. Chui,et al.  Multicenter clinicopathological correlation in dementia. , 1995, The American journal of psychiatry.

[45]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[46]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.

[47]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.